The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial and/or institutional partners, in order to serve the patient needs and for the benefit of the society, as well as to contribute to sustainability of the Institut Pasteur’s resources.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
Researchers from the Institut Pasteur and INSERM have developed the first mouse model for chikungunya virus infection. This animal model mimics both the benign and severe forms of the disease. As a result, the scientists have determined which tissues and cells are infected by the virus in each of these clinical conditions. The development of such an animal model is a major advance, not only at the pathophysiological level, but also because it will allow testing future vaccines and treatments against chikungunya.
Paris, febuary 15, 2008
Following the epidemic that hit the Indian Ocean (especially the French Island of La Réunion) in 2005-2006, and then spread to India, and more recently Italy in September 2007, the main symptoms of chikungunya —fever, joint and muscle pains, and skin rash— are now well known by the medical community and the general public. However, the pathophysiology of this infection remains poorly understood, notably the factors responsible for severe disease with neurological manifestations, which are mainly observed among newborns and the elderly.
In order to better understand how the chikungunya virus infects the human host, a mouse model of infection has been developed by the researchers in the team of Marc Lecuit1 (Microbes and Host Barriers Group, Institut Pasteur/Avenir Team, INSERM Unit 604) in collaboration with Matthew Albert’s team (Immunobiology of Dendritic Cells, Institut Pasteur/INSERM Unit 818) and other researchers and clinicians from the Institut Pasteur. This model carries a deletion of a gene encoding one of the key proteins in the innate antiviral immune response. When only one of the two copies of the gene is deleted, the mice mimic the disease in its benign form. With both versions deleted, and therefore unable to produce the protein, they constitute a model for the severe forms of the infection.
The chikungunya animal model has allowed the researchers to identify the tissue and cell targets of the virus. They have demonstrated that after an initial phase of viral replication in the liver, the infection extends to the joints, muscles, and the skin —the tissues in which seat the symptoms in humans— before disseminating to the central nervous system in the most severe cases. This research also reveals that the principal cell target of the virus is the fibroblast. Furthermore, the researchers have also proved that the disease is more severe among newborn mice, and, through this model, were able to study the mother-to-child transmission of the virus, a complication that was recorded for the first time during the La Réunion outbreak.
The development of this first mouse model provides researchers on chikungunya with an experimental tool that sheds light on the pathophysiology of the infection, and which will make it possible to evaluate future treatments and vaccine candidates against this emerging viral disease in vivo.
1 Professor, Infectious Diseases, Necker-Enfants Malades Hospital, Paris Descartes University, and the Necker-Pasteur Centre for Infectious Diseases.
The Chikungunya virus (in red) affects the joints, one of the tissues in which seat the symptoms in humans. /// Copyright M. Lecuit / Institut Pasteur
“A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease”, PLoS Pathogens, 15 February 2008.
Thérèse Couderc (1,2), Fabrice Chrétien (3,4), Clémentine Schilte (5,6), Olivier Disson (1,2,7), Madly Brigitte (4), Florence Guivel-Benhassine (1,2), Yasmina Touret (8), Georges Barau (8), Nadège Cayet (9), Isabelle Schuffenecker (10), Philippe Desprès (11), Fernando Arenzana-Seisdedos (12,13), Alain Michault (14), Matthew L. Albert (5,6), Marc Lecuit (1,2,7,15)
(1) Microbes and Host Barriers Group, Institut Pasteur, Paris, France
(2) Avenir Team, INSERM U604 Paris, France
(3) Stem Cells and Development Unit, CNRS URA 2578, Institut Pasteur, Paris, France
(4) INSERM, U841, Team 10 Créteil, France; (Public Assistance-Paris Hospitals) Albert Chenevier-Henri Mondor Hospital Group,
Pathology Department, Créteil, France; University of Paris XII, Faculty of Medecine, Créteil, France
(5) Immunobiology and Dendrite Cells Group”, Institut Pasteur, Paris, France
(6) INSERM U818, Paris, France
(7) Bacteria-Cell Interactions Unit, Institut Pasteur, Paris, France
(8) Obstetrics and Gynaecology Department, Reunion South Hospital Group, Saint-Pierre, Reunion Island, France
(9) Ultrastructural Microscopy Platform, Institut Pasteur, Paris, France
(10) National Reference Center for Arboviruses, Institut Pasteur Lyon, France
(11) Flavivirus-Host Molecular Interactions Unit , Institut Pasteur, Paris, France
(12) Molecular Viral Pathogenesis Laboratory, Institut Pasteur, Paris, France
(13) CNRS URA 3015, Paris, France
(14) Laboratory of Microbiology, Reunion South Hospital Group, Saint-Pierre, Reunion Island, France
(15) Necker-Pasteur Centre for Infectious Diseases, Necker-Enfants Malades Hospital (Public Assistance-Paris